ArticleFrontiers in physiology2025
A new SO
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SASP-driven vascular aging: unraveling the transcriptional nexus in endothelial senescence and cardiovascular disease.Histochemistry and cell biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Vitamin D binding protein (VDBP) serves as a key biomarker for vascular injury, offering important applications in both diagnosis and prognosis. However, its precise functional role remains incompletely understood. Methods: We investigated the compound ZSO as a VDBP-interacting compound conferring potent anti-senescence effects. Given that endothelial senescence and calcification drive vascular aging, processes accelerated by high glucose. We assessed the impact of ZSO Results: ZSO treatment markedly alleviated high glucose-induced endothelial cell senescence and calcification Discussion: This study identifies ZSO as a novel small molecule that inhibits endothelial senescence and calcification, and establishes its role in directly targeting VDBP to promote degradation. Furthermore, our findings underscore the critical role of VDBP in vascular aging and calcification and suggest its potential utility as a biomarker for diabetic vascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.